Plasma NfL Levels and Longitudinal Change Rates in and -associated Diseases: from Tailored References to Clinical Applications
Overview
Neurosurgery
Psychiatry
Authors
Affiliations
Objective: Neurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in and cohorts from presymptomatic to clinical stages.
Methods: We analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of and patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of >2 years, during which four PS became prodromal/symptomatic. Associations between pNfL and clinical-genetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cut-offs were determined using the Youden Index.
Results: pNfL levels increased with age in controls, from ~5 to~18 pg/mL (p<0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p<0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p<0.0001), with gene-specific trajectories. patients had higher levels than (86.21 vs 39.49 pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In patients, levels were associated with the phenotype (ALS: 71.76 pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cut-offs differentiating patients from controls by decades.
Conclusions: This study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression.
Trial Registration Numbers: NCT02590276 and NCT04014673.
Sheth U, Oijerstedt L, Heckman M, White L, Heuer H, Lario Lago A Mol Neurodegener. 2025; 20(1):30.
PMID: 40075459 PMC: 11905702. DOI: 10.1186/s13024-025-00821-4.
Plasma Biomarkers in the Distinction of Alzheimer's Disease and Frontotemporal Dementia.
Gomez-Tortosa E, Aguero-Rabes P, Ruiz-Gonzalez A, Wagner-Reguero S, Tellez R, Mahillo I Int J Mol Sci. 2025; 26(3).
PMID: 39940998 PMC: 11818795. DOI: 10.3390/ijms26031231.
Clinical features and progress in diagnosis and treatment of amyotrophic lateral sclerosis.
Yuan D, Jiang S, Xu R Ann Med. 2024; 56(1):2399962.
PMID: 39624969 PMC: 11616751. DOI: 10.1080/07853890.2024.2399962.
Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review.
Liampas I, Kyriakoulopoulou P, Karakoida V, Kavvoura P, Sgantzos M, Bogdanos D Int J Mol Sci. 2024; 25(21).
PMID: 39519389 PMC: 11546606. DOI: 10.3390/ijms252111838.
Benatar M, Wuu J, Huey E, McMillan C, Petersen R, Postuma R Nat Rev Neurol. 2024; 20(6):364-376.
PMID: 38769202 PMC: 11216694. DOI: 10.1038/s41582-024-00961-z.